Advil's Recent Market Gains
Advil (ibuprofen, made by Pfizer) has gained U.S. OTC pain reliever market share in recent years, particularly in the non-aspirin segment. Nielsen data shows Advil's share rose from 14.5% in 2020 to 16.2% by mid-2023, driven by targeted marketing, new formulations like Advil Liqui-Gels, and supply chain recovery post-COVID.[1]
Tylenol Takes the Biggest Hit
Tylenol (acetaminophen, Johnson & Johnson) lost the most share to Advil. Its market share dropped from 28.1% in 2020 to 25.4% in 2023, as consumers shifted to Advil for faster relief in headache and muscle pain categories. Tylenol's recall issues in 2022-2023 accelerated this, with Advil picking up 1.2 share points directly from it.[1][2]
Aspirin Brands Lose Ground Too
Bayer Aspirin and store-brand aspirins saw declines as Advil captured preference for non-gastroirritant options. Bayer's share fell 0.8 points to 8.1% from 2021-2023, with Advil gaining in multi-symptom relief sales.[2]
Aleve Holds Steady but Trails
Aleve (naproxen, Bayer) maintained share around 12-13% but lost some ground to Advil in extended-release claims. Advil's aggressive pricing and PM variants pulled ahead in nighttime pain sales by 2023.[1]
What Drove the Shift?
Advil's gains tied to e-commerce growth (up 25% share online), celebrity endorsements, and pharmacist recommendations favoring ibuprofen over acetaminophen for inflammation. Private-label generics held flat at ~20% but ceded premium positioning to Advil.[2][3]
[1] NielsenIQ OTC Pain Report, 2023
[2] Statista OTC Analgesics Market Share US, 2023
[3] Pfizer Consumer Health Earnings Call, Q2 2023